Search Results

Theralase Technologies Inc. is pleased to announce that it’s lead compound, Ruvidar TM, has been proven effective in the inactivation of various viruses.

Theralase Technologies Inc. has released the Company’s unaudited interim consolidated 1Q2024 financial statements.

Theralase® Technologies Inc. is providing a reminder notice for its Annual General and Special Meeting for shareholders of Theralase® that is scheduled for Wednesday, June 19th at 4:30 pm ET at its corporate head office; specifically, 41 Hollinger Road, Toronto, Ontario, M4B 3G4.

Theralase Technologies Inc. is pleased to announce that it’s lead compound, Ruvidar TM , combined with transferrin to form the compound RuvidarTM, combined with transferrin to form the compound Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”).

Theralase® Technologies Inc. is pleased to announce that it has expanded its clinical team with the hiring of two Clinical Research Associates.

Theralase Technologies Inc. donated two Theralase® TLC-2400 Cool Laser Therapy (“CLT”) systems to the University of Windsor to aid in the research and development of a novel treatment for patients suffering from Parkinson’s Disease (“Parkinson’s”).

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses, has been granted a Canadian patent for a new cancer vaccine.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a Non-Brokered Private Placement offering of units.